



**GIG**  
CYMRU  
**NHS**  
WALES

Bwrdd Iechyd Prifysgol  
Bae Abertawe  
Swansea Bay University  
Health Board

Cadeirydd/Chair: **Emma Woollett**  
Prif Weithredwr/Chief Executive: **Mark Hackett**

**gofalu am ein gilydd, cydweithio, gwella bob amser**  
**caring for each other, working together, always improving**

Rydym yn croesawu gohebiaeth yn y Gymraeg neu'r Saesneg. Atebir gohebiaeth Gymraeg yn y Gymraeg, ac ni fydd hyn yn arwain at oedi.  
We welcome correspondence in Welsh or English. Welsh language correspondence will be replied to in Welsh, and this will not lead to a delay.

## **Cais Rhyddid Gwybodaeth / Freedom of Information request** **Ein Cyf / Our Ref: 22-I-012**

### **You asked:**

#### **Q1. Does your Health Board provide SACT (systemic anti-cancer therapy) treatments for the following conditions?**

- **Cervical cancer** - Yes
- **Endometrial cancer** - Yes

#### **Q2. How many patients were treated for cervical cancer in the past 6 months with the following treatments:**

For the period 1<sup>st</sup> March to 31<sup>st</sup> August 2022

- **Paclitaxel in combination with Platinum and/or Bevacizumab** - 0
- **Pembrolizumab in combination with Platinum and/or Bevacizumab** - 0
- **Platinum standalone or in combination with Bevacizumab** - <5\*
- **Toptecan in combination with Platinum and/or Bevacizumab** - 0
- **Any other SACT** - 0

#### **Q3. How many patients were treated for endometrial cancer in the past 6 months with the following treatments:**

For the period 1<sup>st</sup> March to 31<sup>st</sup> August 2022

- **Dostarlimab** - 0
- **Hormone therapy (Progesterone or Letrozole)** – Not held centrally, only available in patient notes \*\*
- **Pembrolizumab in combination with Lenvatinib** - 0
- **Platinum-based chemotherapy (monotherapy or combination with taxanes, anthracyclines, cyclophosphamide)** - 14
- **Any other SACT** - <5\*

#### **Q4. How many endometrial cancer patients received the following therapies as 1<sup>st</sup> Line treatment in the past 6 months:**

- **Hormone therapy (Progesterone or Letrozole)** – Not held centrally, only available in patient notes \*\*



**Pencadlys BIP Bae Abertawe, Un Porthfa Talbot, Port Talbot, SA12 7BR / Swansea Bay UHB Headquarters, One Talbot Gateway, Port Talbot, SA12 7BR**

Bwrdd Iechyd Prifysgol Bae Abertawe yw enw gweithredu Bwrdd Iechyd Lleol Prifysgol Bae Abertawe  
Swansea Bay University Health Board is the operational name of Swansea Bay University Local Health Board

- **Platinum-based chemotherapy (monotherapy or combination with taxanes, anthracyclines, cyclophosphamide)** – Not held centrally, only available in patient notes \*\*
- **Any other SACT** – Not held centrally, only available in patient notes \*\*

**Q5. Does your Health Board participate in any clinical trials for the treatment of cervical cancer? If so, can you please provide the name of each trial and the number of patients taking part.**

The Health Board is currently not participating in any clinical trials for the treatment of cervical cancer.

**Q6. Does your Health Board participate in any clinical trials for the treatment of endometrial cancer? If so, can you please provide the name of each trial and the number of patients taking part.**

The Health Board is currently not participating in any clinical trials for the treatment of endometrial cancer.

\* Where fewer than 5 has been indicated we are unable to provide you with the exact number of patients as due to the low numbers, there is a potential risk of identifying individuals if this was disclosed. We are therefore withholding this detail under Section 40(2) of the Freedom of Information Act 2000. This information is protected by the General Data Protection Regulation (GDPR) and Data Protection Act 2018 and its disclosure would be contrary to the data protection principles and constitute as unfair and unlawful processing in regard to Articles 5, 6, and 9 of GDPR. This exemption is absolute and therefore there is no requirement to apply the public interest test.

\*\* This information is not held centrally on pharmacy systems. To obtain this information would involve a manual trawl and search of patient records which we have estimated would significantly exceed the 18 hours limit set down by the FOI Act as the reasonable limit. Section 12 of the FOI Act and The Freedom of Information and Data Protection (Appropriate Limit and Fees) Regulation 2004 provides that we are not obliged to spend in excess of 18 hours in any sixty day period locating, retrieving and identifying information in order to deal with a request for information and therefore we are withholding this information at this time.

